免疫治疗相关的恶性肿瘤疗效评价标准纵览  

Overview of the immunotherapy-related response evaluation criteria in malignant tumors

作　　者：蔡其君 尚靖杰[1] 弓健[1] 徐浩[1] Cai Qijun;Shang Jingjie;Gong Jian;Xu Hao(Department of Nuclear Medicine,the First Affiliated Hospital of Jinan University,Guangzhou 510630,China)

机构地区：[1]暨南大学附属第一医院核医学科,广州510630

出　　处：《国际放射医学核医学杂志》2021年第2期111-117,共7页International Journal of Radiation Medicine and Nuclear Medicine

摘　　要：免疫检查点抑制剂(ICIs)作为一种新型治疗药物,极大地丰富了癌症的治疗手段,但随之出现的免疫相关反应模式(如假性进展、延迟反应和超进展等)对现行的恶性肿瘤疗效评价标准提出了挑战。因此,研究者对相关的评价标准进行了一些修订,使其能够更客观准确地评价ICIs的治疗效果,以便更科学地指导临床治疗方案的制定。笔者就近年来提出的免疫治疗相关的恶性肿瘤疗效评价标准进行综述。As a new type of therapeutic drug,immune checkpoint inhibitors(ICIs)has greatly enriched the cancer therapies.However,the subsequent emergence of immune-related response patterns,such as pseudoprogression,delayed response and hyperprogression have challenged the current response evaluation criteria in malignant tumors.Therefore,researchers have constantly revised the relevant evaluation criteria to enable them to assess the therapeutic effects more objectively and guide the formulation of clinical therapy more scientifically.This paper reviews the immunotherapyrelated response evaluation criteria in malignant tumors proposed in recent years.

关 键 词：免疫疗法 正电子发射断层显像术 分子探针 肿瘤疗效评价标准 免疫检查点抑制剂 假性进展 

分 类 号：R730.51[医药卫生—肿瘤]